On March 14, 2022, the first batch of nearly 70,000 doses of Tetanus Vaccine, Adsorbed exported by Chengdu Olymvax Biopharmaceuticals Inc. was shipped to Pakistan.

Tetanus is a fatal infectious disease induced by the toxin-producing Clostridium tetani causing poisoning of the nervous system, which can develop at any age and has a very high case fatality rate. After receiving the tetanus vaccine, the body will be stimulated to produce humoral immune response to prevent tetanus.

OLYMVAX is the first private enterprise in China to obtain the approval number of Tetanus Vaccine, Adsorbed. As the first product of OLYMVAX, its Tetanus Vaccine, Adsorbed was launched on the market in June 2017. It is one of the core products of OLYMVAX. It was the first time for the Company to export its products, giving a milestone in the development history of the Company.

Since its establishment, OLYMVAX has implemented the bidirectional international development strategy of “going global and bringing in”. This export is an opportunity for the Company to internationalize its vaccine products, which was good experience for the team in export sales and laid a solid foundation for subsequent products.